Psychosis research in Asia: advantage from low prevalence of cannabis use.

Tae Young Lee,Jun Soo Kwon

doi:10.1038/s41537-016-0002-4

Abstract

Psychosis research in Asia: advantage from low prevalence of cannabis use.

Highlights

CANNABIS USE AND clinical high risk (CHR) RESEARCH IN ASIA Findings that delta-9-tetrahydrocannabinol (THD), which is the principal active ingredient of cannabis, can induce the experience of acute transient psychotic episodes have fostered a considerable growth of literature on the association of cannabis and psychosis
The rise of consortiums and joint projects, such as NAPLS, PRONIA, and PSYSCAN, has shown that this collaborative effort allow for larger samples and more robust power
Individuals identified as CHR are at highly increased risk for psychosis and have around 30% of risk for developing the illness within 3 years following the initial presentation.[3]

Summary

Introduction

CANNABIS USE AND CHR RESEARCH IN ASIA Findings that delta-9-tetrahydrocannabinol (THD), which is the principal active ingredient of cannabis, can induce the experience of acute transient psychotic episodes have fostered a considerable growth of literature on the association of cannabis and psychosis. The negligible cannabis and other substance-use rates in Asian countries might be able to, at least in part, explain why, for instance, Klauser et al.[6] have reported no abnormality of brain volume or cortical thickness in CHR subjects.

Results

Conclusion